The use of angiotensin-converting enzyme inhibitors in hospitalized patients with COVID-19 is associated with a lower risk of mortality
Mykola Khalangot, Vitaliy Gurianov, Tamara Zakharchenko, Victor Kravchenko, Olena Kovzun, Volodymyr Shupachynskiy, Mykola Tronko · 2025
Read The use of angiotensin-converting enzyme inhibitors in hospitalized patients with COVID-19 is associated with a lower risk of mortality by Mykola Khalangot, Vitaliy Gurianov, Tamara Zakharchenko, Victor Kravchenko, Olena Kovzun, Volodymyr Shupachynskiy, Mykola Tronko (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12749046.txt.
Description
The relationship between the use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), diabetes mellitus (DM), and the risk of death in patients with COVID-19 remains controversial. We hypothesized that DM and certain characteristics of the COVID-19 course during hospital treatment may alter the assessment of the association of ACEIs/ARBs with COVID-19 outcomes.
Catalog record
| CREATOR | Mykola Khalangot, Vitaliy Gurianov, Tamara Zakharchenko, Victor Kravchenko, Olena Kovzun, Volodymyr Shupachynskiy, Mykola Tronko |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |